Bristol-Myers Squibb/$BMY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bristol-Myers Squibb
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
- Ticker
- $BMY
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 32,500
- Headquarters
- Princeton, United States
- Website
- www.bms.com
BMY Metrics
BasicAdvanced
$124B
13.33
$4.54
0.23
$2.51
4.16%
Price and volume
Market cap
$124B
Beta
0.23
52-week high
$68.64
52-week low
$42.52
Average daily volume
13M
Dividend rate
$2.51
Financial strength
Current ratio
1.532
Quick ratio
1.29
Long term debt to equity
1.963
Total debt to equity
2.019
Dividend payout ratio (TTM)
54.89%
Interest coverage (TTM)
9.07%
Profitability
EBITDA (TTM)
18,934
Gross margin (TTM)
71.66%
Net profit margin (TTM)
18.87%
Operating margin (TTM)
31.79%
Effective tax rate (TTM)
22.12%
Revenue per employee (TTM)
$1,510,000
Management effectiveness
Return on assets (TTM)
10.72%
Return on equity (TTM)
46.60%
Valuation
Price to earnings (TTM)
13.333
Price to revenue (TTM)
2.509
Price to book
5.54
Price to tangible book (TTM)
-7.36
Price to free cash flow (TTM)
10.788
Free cash flow yield (TTM)
9.27%
Free cash flow per share (TTM)
5.615
Dividend yield (TTM)
4.14%
Forward dividend yield
4.16%
Growth
Revenue change (TTM)
3.11%
Earnings per share change (TTM)
82.74%
3-year revenue growth (CAGR)
2.87%
10-year revenue growth (CAGR)
10.81%
3-year earnings per share growth (CAGR)
6.51%
10-year earnings per share growth (CAGR)
10.27%
3-year dividend per share growth (CAGR)
3.71%
10-year dividend per share growth (CAGR)
5.21%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
Analyst projections of the future price of Bristol-Myers Squibb stock.
Bulls say / Bears say
Second-quarter revenue rose 6%, with the Growth Portfolio up 15%, and BMS raised its 2026 revenue and earnings outlook. That shows newer medicines are already helping to offset pressure elsewhere. (Reuters)
The FDA approved ZENBEXUS, BMS’s first CELMoD therapy for multiple myeloma, creating a new commercial opportunity in a key cancer market. Its approval was based on Phase 3 results, although continued approval depends on confirming clinical benefit. (Bristol Myers Squibb)
Recent Phase 3 results offer potential longer-term growth beyond today’s best-selling drugs: RYZ101 and admilparant each met a primary trial endpoint. BMS says it will discuss next regulatory steps, though full trial data are still pending. (Bristol Myers Squibb, Bristol Myers Squibb)
Eliquis and Opdivo together accounted for more than half of second-quarter sales, and both face possible US loss of exclusivity in 2028. That concentration leaves BMS exposed if its newer medicines cannot replace those revenues quickly enough. (Fierce Biotech)
Generic competition is already shrinking the legacy portfolio: second-quarter revenue fell 4%, despite strong Eliquis growth, with sharp declines in Revlimid and Pomalyst. Newer products must keep growing just to offset that erosion. (Yahoo Finance)
BMS pushed key milvexian and Cobenfy trial readouts into 2027, rather than expecting results later this year. The delay postpones important pipeline evidence as the company prepares for future patent losses. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 14 Oct 2026.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
Upcoming events
BMY News
AllArticlesVideos
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
Business Insider3 days ago
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
Market Watch3 days ago
Bristol Myers falls 3% despite positive cancer drug trial results
Proactive Investors4 days ago
Funds containing BMY
AllUSDEURGBP
Fund name | Fund size | $BMY weighting |
|---|---|---|
VanEck Morningstar Wide Moat$MOAT | $396M | 2.69% |
VanEck Morningstar Wide Moat€GMVM | €407M | 2.69% |
VanEck Morningstar Wide Moat£MOGB | £354M | 2.69% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 2.20% |
VanEck Morningstar Developed Markets Dividend Leaders€TDIV | €754M | 2.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.